How LDN Helps with Crohn's Disease
If you love anybody who has Crohn's disease, you know how disruptive it can be to their everyday routines. When symptoms intensify, Crohn's disease is sometimes extremely disabling, immediately stopping plans for the day. So, what is this terrible condition called Crohn's disease, and why does it occur?
Crohn's disease is an illness that affects a person's digestive tract. The disease can result in abdominal discomfort, inflammation, severe diarrhea, exhaustion, cachexia, and loss of appetite.
The exact etiology of Crohn's disease is unknown, but experts suspect it is a combination of immune system failure, genetics, environmental factors, and alterations in the gut microbiome. Because research in this field is ongoing, researchers should discover much more in the future.
LDN stands for Low Dose Naltrexone
Naltrexone is an opioid inhibitor that the FDA has licensed to treat opioid and alcohol abuse. The average Naltrexone dose is 50mg per day for people struggling with substance abuse.
Low Dose Naltrexone has also been used with unconfirmed effectiveness for a variety of disorders, including HIV/AIDS, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Lyme disease, multiple sclerosis (MS), and certain other autoimmune diseases at reduced doses (about 5 mg/day).
How LDN Might Aid in the Treatment of Crohn's Disease
Thousands of people worldwide have used Low Dose Naltrexone to treat Crohn's disease symptoms during the last two decades, with many having highly favorable outcomes. This remarkable feat and LDN's efficacy in treating other inflammation-based ailments have given rise to devoted community outreach campaigns of LDN aficionados and the LDN Research Trust, a UK-based charity.
While substantial clinical trials of LDN's impact on Crohn's disease have yet to be published, data from limited clinical trials have been promising. Here's a handful of the significant findings from research conducted over the past twenty years:
Patients who got LDN had a considerable increase in their standard of living. According to a 2007 experiment, investigators indicated that treatment with LDN is beneficial and safe in people with active Crohn's disease symptoms
According to a 2011 research, 88 percent of patients treated with LDN saw at least a 70-point decrease in Crohn's Disease Activity Index scores. After three months, 33 percent entered remission with a Crohn's disease endoscopy index severity (CDEIS) grade less than 6. "Naltrexone boosts regulation of gut microbiome activity in people with moderate to severe Crohn's disease compared to those who took the placebo," the scientists found.
A study in 2013 found that children with moderate to severe Crohn's disease PCDAI (Pediatric Crohn's Disease Activity Index) scores were substantially lower than pretreatment values in just two months. As a result, the researchers declared that Naltrexone treatments appear safe when provided to kids with Crohn's disease because it helps mitigate major symptoms.
Lastly, a 2018 study discovered that "Naltrexone enhances epithelial barrier function firsthand by optimizing tissue repair and minimizing mucosal ER stressors. The investigators asserted that a low-dose Naltrexone treatment plan is appropriate and reliable. It could also be recognized as a therapy for refractory IBD patients.